{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:27:52Z","timestamp":1760909272196,"version":"build-2065373602"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ctrv.2021.102250","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T23:05:47Z","timestamp":1623798347000},"page":"102250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6759-9351","authenticated-orcid":false,"given":"Kaushal","family":"Parikh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizza E.L.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2784-5076","authenticated-orcid":false,"given":"Paolo","family":"Bironzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9462-875X","authenticated-orcid":false,"given":"Jordi","family":"Remon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2021.102250_b0005","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S1470-2045(17)30445-X","article-title":"Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study","volume":"18","author":"Gatta","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102250_b0010","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102250_b0015","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S1470-2045(16)30123-1","article-title":"Novel therapeutic targets on the horizon for lung cancer","volume":"17","author":"Tan","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102250_b0020","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ctrv.2021.102250_b0025","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ctrv.2021.102250_b0030","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/S1470-2045(19)30532-7","article-title":"Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial","volume":"20","author":"Ceresoli","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102250_b0035","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.cllc.2020.06.025","article-title":"Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901","volume":"21","author":"Dudek","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2021.102250_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30362-3","article-title":"Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial","author":"de Gooijer","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ctrv.2021.102250_b0045","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102250_b0050","first-page":"791","article-title":"Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends","volume":"14","author":"Montanaro","year":"2003","journal-title":"Cancer Causes Control CCC"},{"key":"10.1016\/j.ctrv.2021.102250_b0055","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1078-0432.CCR-11-2259","article-title":"Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma","volume":"18","author":"Carbone","year":"2012","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102250_b0060","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2021.102250_b0065","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102250_b0070","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102250_b0075","first-page":"1036","article-title":"B7\u2013H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"10.1016\/j.ctrv.2021.102250_b0080","doi-asserted-by":"crossref","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedr\u00e9s","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2021.102250_b0085","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2019.02.001","article-title":"Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28\u20138 pharmDx assays","volume":"87","author":"Chapel","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2021.102250_b0090","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.cllc.2019.04.010","article-title":"Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort","volume":"20","author":"Brosseau","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2021.102250_b0095","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/2326-6066.CIR-16-0171","article-title":"Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors","volume":"4","author":"Awad","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2021.102250_b0100","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1002\/cncr.26143","article-title":"Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma","volume":"117","author":"Burt","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2021.102250_b0105","first-page":"124","article-title":"Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma","volume":"13","author":"Patil","year":"2018","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"10.1016\/j.ctrv.2021.102250_b0110","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001601","article-title":"Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification","volume":"9","author":"Alay","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2021.102250_b0115","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative Molecular Characterization of Malignant Pleural Mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2021.102250_b0120","doi-asserted-by":"crossref","unstructured":"Muller S, Victoria Lai W, Adusumilli PS, Desmeules P, Frosina D, Jungbluth A, et al. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. Mod Pathol Off J U S Can Acad Pathol Inc 2020;33:303\u201311. https:\/\/doi.org\/10.1038\/s41379-019-0364-z.","DOI":"10.1038\/s41379-019-0364-z"},{"key":"10.1016\/j.ctrv.2021.102250_b0125","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2021.102250_b0130","first-page":"276","article-title":"Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma","volume":"14","author":"Mansfield","year":"2019","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"10.1016\/j.ctrv.2021.102250_b0135","first-page":"157","article-title":"Does Chromothripsis Make Mesothelioma an Immunogenic Cancer?","volume":"14","author":"Carbone","year":"2019","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"10.1016\/j.ctrv.2021.102250_b0140","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2010.12.004","article-title":"Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma","volume":"72","author":"Ceresoli","year":"2011","journal-title":"Lung Cancer Amst Neth"},{"key":"10.1016\/j.ctrv.2021.102250_b0145","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.lungcan.2013.11.011","article-title":"Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"84","author":"Zucali","year":"2014","journal-title":"Lung Cancer Amst Neth"},{"key":"10.1016\/j.ctrv.2021.102250_b0150","doi-asserted-by":"crossref","unstructured":"Pagano M, Ceresoli GL, Zucali PA, Pasello G, Garassino MC, Grosso F, et al. Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): Results of Italian Rames Study. J Clin Oncol 2020;38:9004\u20139004. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.9004.","DOI":"10.1200\/JCO.2020.38.15_suppl.9004"},{"key":"10.1016\/j.ctrv.2021.102250_b9000","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.1200\/JCO.2021.39.15_suppl.8507","article-title":"A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma","volume":"39","author":"Fennell","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102250_b0155","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.annonc.2019.12.009","article-title":"Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17\/16)","volume":"31","author":"Metaxas","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2021.102250_b0160","doi-asserted-by":"crossref","first-page":"S339","DOI":"10.1016\/j.jtho.2018.08.277","article-title":"Phase II Trial of Pembrolizumab (NCT02399371) In Previously-Treated Malignant Mesothelioma (MM): Final Analysis","volume":"13","author":"Desai","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2021.102250_b0165","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102250_b0170","first-page":"1569","article-title":"Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"10.1016\/j.ctrv.2021.102250_b0175","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102250_b0180","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2021.102250_b0185","first-page":"1784","article-title":"Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma","volume":"13","author":"Metaxas","year":"2018","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"10.1016\/j.ctrv.2021.102250_b0190","article-title":"Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population","volume":"1","author":"Ahmadzada","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.ctrv.2021.102250_b0195","doi-asserted-by":"crossref","unstructured":"Cantini L, Belderbos RA, Gooijer CJ, Dumoulin DW, Cornelissen R, Baart S, et al. Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program. Transl Lung Cancer Res 2020;9:1169\u201379. https:\/\/doi.org\/10.21037\/tlcr-19-686.","DOI":"10.21037\/tlcr-19-686"},{"key":"10.1016\/j.ctrv.2021.102250_b0200","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9\u201315) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2021.102250_b0205","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jtho.2021.01.323","article-title":"Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial","volume":"16","author":"Fennell","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2021.102250_b0210","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102250_b0215","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabr\u00f2","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ctrv.2021.102250_b0220","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102250_b0225","doi-asserted-by":"crossref","unstructured":"Ramalingam SS, Ciuleanu TE, Pluzanski A, Lee J-S, Schenker M, Bernabe Caro R, et al. Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1. J Clin Oncol 2020;38:9500\u20139500. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.9500.","DOI":"10.1200\/JCO.2020.38.15_suppl.9500"},{"key":"10.1016\/j.ctrv.2021.102250_b0230","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ctrv.2021.102250_b0235","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabr\u00f2","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ctrv.2021.102250_b0240","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ctrv.2021.102250_b0245","first-page":"4490","article-title":"Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors","volume":"63","author":"Nowak","year":"2003","journal-title":"Cancer Res"},{"issue":"170","key":"10.1016\/j.ctrv.2021.102250_b0250","first-page":"4905","article-title":"Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells","volume":"2003","author":"Nowak","year":"1950","journal-title":"J Immunol Baltim Md"},{"key":"10.1016\/j.ctrv.2021.102250_b0255","doi-asserted-by":"crossref","unstructured":"Forde PM, Sun Z, Anagnostou V, Kindler HL, Purcell WT, Goulart BHL, et al. PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)\u2014A PrECOG LLC study. J Clin Oncol 2020;38:9003\u20139003. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.9003.","DOI":"10.1200\/JCO.2020.38.15_suppl.9003"},{"key":"10.1016\/j.ctrv.2021.102250_b0260","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz266","article-title":"Second\/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD)","volume":"30","author":"Zalcman","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2021.102250_b0265","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1016\/j.jtho.2021.01.141","article-title":"Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189","volume":"16","author":"Gray","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2021.102250_b0270","doi-asserted-by":"crossref","first-page":"S826","DOI":"10.1016\/j.annonc.2020.08.1592","article-title":"Hyperprogressive disease (HPD) upon first-line PD-1\/PD-L1 inhibitors (ICI) as single agent or in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients (pts)","volume":"31","author":"Ferrara","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2021.102250_b0275","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1016\/j.jtho.2016.11.241","article-title":"Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057","volume":"12","author":"Peters","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2021.102250_b0280","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11523-017-0517-2","article-title":"Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study","volume":"12","author":"Gottfried","year":"2017","journal-title":"Target Oncol"},{"key":"10.1016\/j.ctrv.2021.102250_b0285","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.lungcan.2017.07.038","article-title":"Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer","volume":"112","author":"Reck","year":"2017","journal-title":"Lung Cancer Amst Neth"},{"key":"10.1016\/j.ctrv.2021.102250_b0290","doi-asserted-by":"crossref","unstructured":"Watanabe T, Okuda K, Murase T, Moriyama S, Haneda H, Kawano O, et al. Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma. Oncotarget 2018;9:20769\u201380. https:\/\/doi.org\/10.18632\/oncotarget.25100.","DOI":"10.18632\/oncotarget.25100"},{"key":"10.1016\/j.ctrv.2021.102250_b0295","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1356146","article-title":"Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma","volume":"6","author":"Terra","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2021.102250_b0300","doi-asserted-by":"crossref","first-page":"E7759","DOI":"10.1073\/pnas.1609376113","article-title":"Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma","volume":"113","author":"Spranger","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2021.102250_b0305","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102250_b0310","doi-asserted-by":"crossref","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","author":"Nasu","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2021.102250_b0315","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1612074113","article-title":"High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma","author":"Yoshikawa","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2021.102250_b0320","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-019-0620-3","article-title":"BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma","author":"Shrestha","year":"2019","journal-title":"Genome Med"},{"key":"10.1016\/j.ctrv.2021.102250_b0325","doi-asserted-by":"crossref","unstructured":"Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, et al. Extrapleural pneumonectomy versus pleurectomy\/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008;135:620\u20136, 626.e1-3. https:\/\/doi.org\/10.1016\/j.jtcvs.2007.10.054.","DOI":"10.1016\/j.jtcvs.2007.10.054"},{"key":"10.1016\/j.ctrv.2021.102250_b0330","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-038892","article-title":"Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma","volume":"10","author":"Lim","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.ctrv.2021.102250_b0335","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40364-021-00264-1","article-title":"Anti-Mesothelin CAR T cell therapy for malignant mesothelioma","volume":"9","author":"Castelletti","year":"2021","journal-title":"Biomark Res"},{"key":"10.1016\/j.ctrv.2021.102250_b0340","doi-asserted-by":"crossref","unstructured":"Adusumilli PS, Zauderer MG, Rusch VW, O\u2019Cearbhaill R, Zhu A, Ngai D, et al. Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent. J Clin Oncol 2019;37:2511\u20132511. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.2511.","DOI":"10.1200\/JCO.2019.37.15_suppl.2511"},{"key":"10.1016\/j.ctrv.2021.102250_b0345","unstructured":"https:\/\/investors.tcr2.com\/news-releases\/news-release-details\/tcr2-therapeutics-announces-recist-responses-first-tc-210-dose (assessed 22 April 2021) n.d."},{"key":"10.1016\/j.ctrv.2021.102250_b0350","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.annonc.2020.10.474","article-title":"Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial","volume":"32","author":"Hiltbrunner","year":"2021","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2021.102250_b0355","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.201508-1573OC","article-title":"Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma","volume":"193","author":"Cornelissen","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ctrv.2021.102250_b0360","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1164\/rccm.200909-1465OC","article-title":"Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma","volume":"181","author":"Hegmans","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ctrv.2021.102250_b0365","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1158\/1538-7445.AM2019-2249","article-title":"Checkpoint inhibitor therapy after dendritic cell vaccination elicits tumor response in mesothelioma patients","volume":"79","author":"Cornelissen","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102250_b0370","doi-asserted-by":"crossref","first-page":"7483","DOI":"10.1158\/1078-0432.CCR-17-2169","article-title":"A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma","volume":"23","author":"Zauderer","year":"2017","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102250_b0375","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.1158\/1078-0432.CCR-19-0070","article-title":"Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma","volume":"25","author":"Hassan","year":"2019","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102250_b0380","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1089\/hum.2008.036","article-title":"Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma","volume":"19","author":"Kelly","year":"2008","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ctrv.2021.102250_b0385","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.ymthe.2018.02.015","article-title":"Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion","volume":"26","author":"Aggarwal","year":"2018","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.ctrv.2021.102250_b0390","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00262-020-02534-7","article-title":"Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy","volume":"69","author":"Voloshin","year":"2020","journal-title":"Cancer Immunol Immunother CII"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737221000980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737221000980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:27:15Z","timestamp":1759656435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737221000980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":79,"alternative-id":["S0305737221000980"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102250","relation":{},"ISSN":["0305-7372"],"issn-type":[{"type":"print","value":"0305-7372"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102250","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102250"}}